Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01457118 · ClinicalTrials.gov registry record · Phase 2
An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies
A Phase 2 study, sponsored by Nektar Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT01457118 is a Phase 2 study that has completed, run by Nektar Therapeutics. The registered enrollment target is 27 participants.
The verdict
NCT01457118, a Phase 2 study, has completed, sponsored by Nektar Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
The study objective of this open label, multicenter study is to provide access to NKTR-102 treatment to subjects previously enrolled in a NKTR-102 study who are without signs of disease progression since receiving NKTR-102. In addition the study will evaluate the safety of continued exposure to NKTR-102, observe disease status and survival status in subjects receiving NKTR-102, and evaluate the efficacy of NKTR-102 in subjects with advanced or metastatic solid tumors.
Interventions
- DRUG NKTR-102 145 mg/m2
- DRUG NKTR-102 120 mg/m2
- DRUG NKTR-102 95 mg/m2
- DRUG NKTR-102 50 mg/m2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2011-10 |
| Est. Completion | 2017-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01457118
The ClinicalTrials.gov registry entry for NCT01457118 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nektar Therapeutics, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which NKTR-102 145 mg/m2 is the first listed.
NCT01457118 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01457118 about?
NCT01457118 is a clinical study titled "An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies". The study objective of this open label, multicenter study is to provide access to NKTR-102 treatment to subjects previously enrolled in a NKTR-102 study who are without signs of disease progression since receiving NKTR-102. In addition the study will evaluate the safety of continued exposure to NKT...
What is the current status of trial NCT01457118?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2011-10. Estimated completion is 2017-11.
What interventions are being tested in trial NCT01457118?
The interventions under investigation include: NKTR-102 145 mg/m2 (DRUG), NKTR-102 120 mg/m2 (DRUG), NKTR-102 95 mg/m2 (DRUG), NKTR-102 50 mg/m2 (DRUG).
Who is sponsoring clinical trial NCT01457118?
This trial is sponsored by Nektar Therapeutics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.